Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology Most often read

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Most often read

Vol. 31. Issue. 1

85727

Anti-hepatitis B virus activity of food nutrients and potential mechanisms of action

Alexis Jose-Abrego, Ingrid Rivera-Iñiguez, Luis A. Torres-Reyes, Sonia Roman

Ann Hepatol. 2023;28:100766

85727

Full text access

Share

31471

Intravenous albumin in cirrhosis: Updated clinical uses and novel perspectives

Roberta Gagliardi, Nicola Zeni, Salvatore Piano

Ann Hepatol. 2023;28:101150

31471

Full text access

Share

24884

Liver diseases: Perspective from the Philippines

Eric David Ornos, Karl Jeffrey Murillo, Janus P. Ong

Ann Hepatol. 2023;28:101085

24884

Full text access

Share

20056

A thorny matter: Spur cell anemia

Ruchi Sharma, Carol J. Holman, Kyle E. Brown

Ann Hepatol. 2023;28:100771

20056

Open access

Share

15118

New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD

Louise Torres, Alice Schuch, Larisse Longo, Bruna Bressan Valentini, Gabriela Schneider Galvão, Eduardo Luchese, Carlos Pinzon, Rodrigo Bartels, Mário Reis Álvares-da-Silva

Ann Hepatol. 2023;28:100774

15118

Open access

Share

14933

Consensus document on acute-on-chronic liver failure (ACLF) established by the Mexican Association of Hepatology

Aldo Torre, Laura Esthela Cisneros-Garza, Mauricio Castillo-Barradas, Nalu Navarro-Alvarez, Ricardo Sandoval-Salas, María Sarai González-Huezo, José Luís Pérez-Hernández, Osvely Méndez-Guerrero, ... Francisco Alfonso Solís-Galindo

Ann Hepatol. 2023;28:101140

14933

Full text access

Share

14308

Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents

Diego García-Compeán, Ramesh Kumar, Ángel Noe del Cueto-Aguilera, Héctor Jesús Maldonado-Garza, Jesús Zacarías Villarreal-Pérez

Ann Hepatol. 2023;28:100751

14308

Full text access

Share

11195

Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms

Xiaoyi Wang, Zhen Yang, Ying Ran, Long Li, Bangmao Wang, Lu Zhou

Ann Hepatol. 2023;28:101121

11195

Full text access

Share

10550

What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease?

Ingrid Rivera-Iñiguez, Arturo Panduro, Sonia Roman, Karina González-Aldaco

Ann Hepatol. 2023;28:100874

10550

Open access

Share

8311

Immunotolerance in liver transplantation: a primer for the clinician

Juanita Pérez-Escobar, Jose Victor Jimenez, Erika Faride Rodríguez-Aguilar, Maximiliano Servín-Rojas, Jesus Ruiz-Manriquez, Luisa Safar-Boueri, Eduardo Carrillo-Maravilla, Miquel Navasa, Ignacio García-Juárez

Ann Hepatol. 2023;28:100760

8311

Open access

Share

8110

Severe anemia is associated with increased short-term and long-term mortality in patients hospitalized with cirrhosis

Haotang Ren, Hai Li, Guohong Deng, Xianbo Wang, Xin Zheng, Yan Huang, Jinjun Chen, Zhongji Meng, ... Yu Shi

Ann Hepatol. 2023;28:101147

8110

Full text access

Share

7104

Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis

Daniela Contreras, Alejandra González-Rocha, Patricia Clark, Simón Barquera, Edgar Denova-Gutiérrez

Ann Hepatol. 2023;28:100873

7104

Open access

Share

6307

Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists

Lucy Gracen, Withma Muthukumara, Melanie Aikebuse, Anthony Russell, James O'Beirne, Katharine M. Irvine, Suzanne Williams, Gaurav Puri, ... Elizabeth E. Powell

Ann Hepatol. 2023;28:101142

6307

Full text access

Share

6247

Metabolic dysfunction: The silenced connection with fatty liver disease

Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez

Ann Hepatol. 2023;28:101138

6247

Full text access

Share

6111

Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study

Yongwu Chen, Xiuli Yang, Yanfei Shao, Hongying Zhao, Jinying Jiang, Ping Huang, Yi Lu, Zixue Xuan

Ann Hepatol. 2023;28:101099

6111

Full text access

Share

6080

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis

Mark Muthiah, Cheng Han Ng, Kai En Chan, Clarissa Elysia Fu, Wen Hui Lim, Darren Jun Hao Tan, Benjamin Nah, Gwyneth Kong, ... Mazen Noureddin

Ann Hepatol. 2023;28:100762

6080

Open access

Share

5950

The treatment of diabetes in advanced liver disease: change of a paradigm

Maria Letizia Petroni, Lucia Brodosi, Giulio Marchesini

Ann Hepatol. 2023;28:100772

5950

Open access

Share

5435

Systematic review and meta-analysis: Transient elastography compared to liver biopsy for staging of liver fibrosis in primary biliary cholangitis

Luis Antonio Manzo-Francisco, Jorge Aquino-Matus, Dèsirée Vidaña-Pérez, Misael Uribe, Norberto Chavez-Tapia

Ann Hepatol. 2023;28:101107

5435

Full text access

Share

5359

Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina

Federico Guillermo Villamil, Manuel Barbero, Nancy Elena Massenzio, Sandra Mónica Giani, Shigeru Kozima, Fernando Mario Cairo, Rodrigo Agustín Belloni, Javier Mariani, ... Patricia Eugenia Gallardo

Ann Hepatol. 2023;28:101111

5359

Full text access

Share

4994

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir

Fa- Da Wang, Jing Zhou, Lan-Qing Li, Yu-Jing Li, Meng-Lan Wang, Ya-Chao Tao, Dong-Mei Zhang, Yong-Hong Wang, En-Qiang Chen

Ann Hepatol. 2023;28:101119

4994

Full text access

Share

Article options

Tools